Publications

Below is a list of published papers relating to clinical trials of Sativex. Papers are listed in chronological order. GW continues to submit papers for publication on a regular basis and this page will be updated as new publications emerge.

Rog D, Nurmikko T, Young C. Oromucosal delta-9-Tetrahydrocannabinol/Cannabidiol for Neuropathic Pain Associated with Multiple Sclerosis: An Uncontrolled,Open-Label, 2-Year Extension Trial. Clinical Therapeutics. 2007;29(9):2068-79.

Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology. 2007;14:290-6.

Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis. 2006;12(5):639-45.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50-2.

Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy. 2006;7(5):607-15.

Rog DJ, Nurmikko TJ, Friede T, Young AH. Randomized controlled trial of cannabis medicine in central pain due to multiple sclerosis. Neurology. 2005;65:812-9.

Perras C. Sativex for the management of multiple sclerosis symptoms. Issues in Emerging Health Technologies. 2005;72:1-4.

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis. 2004;10:1-8.

Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia. 2004;59(5):440-52.

Nicholson AN, Turner C, Stone BM, Robson P. Effect of Delta-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. Journal of Clinical Psychopharmacology. 2004;24(3):305-13.

Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis. 2004 Aug;10(4):425-33.

Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.

Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation. 2003;17(1):21-9.

Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses. 2006;66(2):234-46.

Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007 Aug;4(8):1729-43.

Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management. 2008;4(1):245-59.

Pérez J. Combined cannabinoid therapy via na oromucosal spray. Drugs of Today. 2006;42(8):495-501.

Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert opinion on pharmacotherapy. 2006 Apr;7(5):607-15.